Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Downregulation of Betaig-h3 gene is causally linked to tumorigenic phenotype in asbestos treated immortalized human bronchial epithelial cells

Abstract

Although Betaig-h3 gene has been suggested to modulate cell adhesion and tumor formation, its physiological functions are not well understood. Using human papillomavirus immortalized human bronchial epithelial (BEP2D) cells, we found that Betaig-h3 expression was markedly decreased in asbestos-induced tumorigenic cells. Fusion of tumorigenic and control BEP2D cells resulted in the recovery of Betaig-h3 gene expression to control level and the loss of tumorigenic phenotype. Furthermore, ectopic expression of Betaig-h3 gene in asbestos-induced tumorigenic cells inhibited cell growth in vitro, anchorage independent phenotype, as well as tumorigenicity in nude mice. Betaig-h3 gene is ubiquitously expressed in various normal human tissues, with the exception of the brain, where there is little or no expression. In contrast, there was a decrease or absence in expression of the Betaig-h3 gene in 14 human tumor cell lines of diverse histological types examined, when compared with normal human cells or tissues. The result strongly suggests that loss of Betaig-h3 expression is a frequent event in human cancer and causally related to acquisition of tumorigenic phenotype in asbestos-treated BEP2D cells.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Billings PC, Herrick DJ, Howard PS, Kucich U, Engelsberg BN, Rosenbloom J . 2000a Am. J. Respir. Cell Mol. Biol. 22: 352–359

  • Billings PC, Herrick DJ, Kucich U, Engelsberg BN, Abrams WR, Macarak EJ, Rosenbloom J, Howard PS . 2000b J. Cell Biochem. 79: 261–273

  • Brezinova J, Zemanova Z, Cermak J, Michalova K . 2000 Cancer Genet. Cytogenet. 117: 45–49

  • Brody AR, Liu JY, Brass D, Corti M . 1997 Environ. Health Perspect. 105: suppl 5 1165–1171

  • Bron AJ . 2000 Cornea 19: 699–711

  • Fearon ER, Pierceall WE . 1995 Cancer Surv. 24: 3–17

  • Fitzpatrick DR, Peroni DJ, Bielefeldt-Ohmann H . 1995 Am. J. Respir. Cell Mol. Biol. 12: 455–460

  • Genini M, Schwalbe P, Scholl FA, Schafer BW . 1996 Int. J. Cancer 66: 571–577

  • Gerwin BI . 1994 Am. J. Respir. Cell Mol. Biol. 11: 507–508

  • Hei TK, Piao CQ, He ZY, Vannais D, Waldren CA . 1992 Cancer Res. 52: 6305–6309

  • Hei TK, Wu LJ, Piao CQ . 1997 Environ. Health Perspect. 105: suppl 5 1085–1088

  • Hei TK, Xu A, Louie D, Zhao YL . 2000 Inhal. Toxicol. 12: suppl 3 141–147

  • Heintz NH, Janssen YM, Mossman BT . 1993 Proc. Natl. Acad. Sci. USA 90: 3299–3304

  • Jagirdar J, Lee TC, Reibman J, Gold LI, Aston C, Begin R, Rom WN . 1997 Environ. Health Perspect. 105: suppl 5 1197–1203

  • Jaurand MC . 1997 Environ. Health Perpect. 105: suppl 5 1073–1084

  • Kamp DW, Weitzman SA . 1999 Thorax 54: 638–652

  • Kane AB . 1996 IARC Sci. Publ. 140: 11–34

  • Kim JE, Kim EH, Han EH, Park RW, Park IH, Jun SH, Kim JC, Young MF, Kim IS . 2000 J. Cell Biochem. 77: 169–178

  • Mossman BT, Kamp DW, Weitzman SA . 1996 Cancer Invest. 14: 464–478

  • Mossman BT, Faux S, Janssen Y, Jimenez LA, Timblin C, Zanella C, Goldberg J, Walsh E, Barchowsky A, Driscoll K . 1997 Environ. Health Perspect. 105: suppl 5 1121–1125

  • Murthy SS, Testa JR . 1999 J. Cell. Physiol. 180: 150–157

  • Ni Z, Liu YQ, Keshava N, Zhou G, Whong W, Ong T . 2000 Mutation Res. 468: 87–92

  • Pass HI, Mew DJ . 1996 J. Cell Biochem. Suppl. 24: 142–151

  • Peralta RC, Casson AG, Wang RN, Keshavjee S, Redston M, Bapat B . 1998 Int. J. Cancer 78: 600–605

  • Perdue TD, Brody AR . 1994 J. Histochem. Cytochem. 42: 1061–1070

  • Piao CQ, Zhao YL, Hei TK . 2001 Oncogene 20: 7301–7306

  • Robledo R, Mossman B . 1999 J. Cell. Physiol. 180: 158–166

  • Salih HR, Nussler V . 2001 Eur. J. Med. Res. 6: 323–332

  • Schenker T, Trueb B . 1998 Exp. Cell Res. 239: 161–168

  • Skonier J, Neubauer M, Madisen L, Bennett K, Plowman GD, Purchio AF . 1992 DNA Cell Biol. 11: 511–522

  • Skonier J, Bennett K, Rothwell V, Kosowski S, Plowman G, Wallace P, Edelhoff S, Disteche C, Neubauer M, Marquardt H . 1994 DNA Cell Biol. 13: 571–584

  • Suzuki M, Piao CQ, Zhao YL, Hei TK . 2001 Int. J. Mol. Med. 8: 43–47

  • Willey JC, Broussoud A, Sleemi A, Bennett WP, Cerutti P, Curtis CC . 1991 Cancer Res. 51: 5370–5377

  • Wu X, Zhao Y, Kemp BL, Amos CI, Siciliano MJ, Spitz MR . 1998 Int. J. Cancer 79: 490–493

  • Xu A, Wu LJ, Santella RM, Hei TK . 1999 Cancer Res. 59: 5922–5926

  • Zanella CL, Posada J, Tritton TR, Mossman BT . 1996 Cancer Res. 56: 5334–5338

  • Zhao YL, Piao CQ, Wu LJ, Suzuki M, Hei TK . 2000 Carcinogenesis 21: 2005–2010

Download references

Acknowledgements

The author thanks Dr Paul C Billings for kindly providing anti-Betaigh3 antibody. Work supported in part by grants from the National Institute of Health CA49062, ES07890 and Environmental Health Center Grant P30 ES 09089.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yong L Zhao.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhao, Y., Piao, C. & Hei, T. Downregulation of Betaig-h3 gene is causally linked to tumorigenic phenotype in asbestos treated immortalized human bronchial epithelial cells. Oncogene 21, 7471–7477 (2002). https://doi.org/10.1038/sj.onc.1205891

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205891

Keywords

This article is cited by

Search

Quick links